Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Operating Expenses (2017 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Other Operating Expenses for 9 consecutive years, with $1.3 million as the latest value for Q1 2026.

  • For Q1 2026, Other Operating Expenses rose 21.57% year-over-year to $1.3 million; the TTM value through Mar 2026 reached $3.0 million, down 98.51%, while the annual FY2024 figure was $200.0 million, N/A changed from the prior year.
  • Other Operating Expenses hit $1.3 million in Q1 2026 for Agios Pharmaceuticals, down from $1.7 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $200.0 million in Q3 2024 and bottomed at -$9.9 million in Q4 2022.
  • Average Other Operating Expenses over 5 years is $17.3 million, with a median of $1.4 million recorded in 2024.
  • On a YoY basis, Other Operating Expenses climbed as much as 122.6% in 2022 and fell as far as 474.57% in 2022.
  • Agios Pharmaceuticals' Other Operating Expenses stood at -$9.9 million in 2022, then soared by 111.19% to $1.1 million in 2023, then skyrocketed by 17950.54% to $200.0 million in 2024, then crashed by 99.15% to $1.7 million in 2025, then fell by 22.5% to $1.3 million in 2026.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $1.3 million, $1.7 million, and $1.1 million for Q1 2026, Q2 2025, and Q1 2025 respectively.